Spondyloarthritis

Assessing Diagnostic Challenges in Axial Spondyloarthritis

Assessing Diagnostic Challenges in Axial Spondyloarthritis

By

Axial spondyloarthritis is often delayed or missed as a diagnosis, leading to poor long-term outcomes and decreased quality of life.

Pelvic Orientation From Standing to Sitting Adjusted by Global Spinal Alignment in AS

Pelvic Orientation From Standing to Sitting Adjusted by Global Spinal Alignment in AS

By

Pelvic orientation was adjusted by global spinal alignment in patients with ankylosing spondylitis.

Work Instability Linked to Fatigue, Depression in Ankylosing Spondylitis

Work Instability Linked to Fatigue, Depression in Ankylosing Spondylitis

By

Fatigue and depressive symptoms had a negative effect on work stability in patients with ankylosing spondylitis.

Abatacept Improved Patient-Reported Outcomes in Psoriatic Arthritis

Abatacept Improved Patient-Reported Outcomes in Psoriatic Arthritis

By

Abatacept treatment improved patient-reported outcomes in patients with psoriatic arthritis compared with placebo.

Very Low Disease Activity Validated as Remission Target for Psoriatic Arthritis

Very Low Disease Activity Validated as Remission Target for Psoriatic Arthritis

By

Data suggest that very low disease activity may be an appropriate target for remission in patients with psoriatic arthritis treated with golimumab.

Secukinumab Provides Sustained Remission for Psoriatic Arthritis in Post Hoc Analysis

Secukinumab Provides Sustained Remission for Psoriatic Arthritis in Post Hoc Analysis

By

A post hoc analysis of the FUTURE 2 study showed that secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis.

Ixekizumab Compared With Adalimumab in Head-to-Head PsA Study

Ixekizumab Compared With Adalimumab in Head-to-Head PsA Study

By

The SPIRIT H2H trial (N=566) randomized PsA patients to receive ixekizumab (160mg starting dose followed by 80mg every 4 weeks) or adalimumab (40mg every 2 weeks) for 52 weeks.

Metabolic Syndrome, Psoriatic Arthritis Highly Prevalent in Patients With Plaque Psoriasis

Metabolic Syndrome, Psoriatic Arthritis Highly Prevalent in Patients With Plaque Psoriasis

By

Metabolic syndrome and psoriatic arthritis were highly prevalent comorbidities in patients with plaque psoriasis.

Managing Psoriatic Arthritis: Updated 2018 Recommendations From ACR/NPF

Managing Psoriatic Arthritis: Updated 2018 Recommendations From ACR/NPF

By

The American College of Rheumatology and the National Psoriasis Foundation have released 2018 joint recommendations for the treatment of psoriatic arthritis.

Acute Anterior Uveitis Incidence Reduced With Golimumab in Ankylosing Spondylitis

Acute Anterior Uveitis Incidence Reduced With Golimumab in Ankylosing Spondylitis

By

Researchers observed a significant reduction in the incidence of acute anterior uveitis among patients with ankylosing spondylitis treated with golimumab.

Immunogenicity of Golimumab Validated Using Novel Anti-Drug Antibody Detection Assay

Immunogenicity of Golimumab Validated Using Novel Anti-Drug Antibody Detection Assay

By

Antidrug antibody incidence was higher using drug-tolerant vs original enzyme immunoassays in patients treated with golimumab.

New Psoriatic Arthritis Guidelines Recommend TNFi as First-Line Therapy Option

New Psoriatic Arthritis Guidelines Recommend TNFi as First-Line Therapy Option

By

The guideline is jointly authored by the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).

Using Acute-Phase Reactants to Evaluate Inflammation in Patients With Psoriatic Arthritis

Using Acute-Phase Reactants to Evaluate Inflammation in Patients With Psoriatic Arthritis

By

Data regarding assessment of systemic inflammation using acute-phase reactants are limited.

CRP Levels May Predict Treatment Response in Ankylosing Spondylitis

CRP Levels May Predict Treatment Response in Ankylosing Spondylitis

By

C-reactive protein levels may be an effective predictive measure to assess treatment response in patients with ankylosing spondylitis.

Filgotinib Safe, Effective for Treatment of Active Ankylosing Spondylitis

Filgotinib Safe, Effective for Treatment of Active Ankylosing Spondylitis

By

The TORTUGA trial investigated the efficacy and safety of filgotinib for the treatment of patients with active ankylosing spondylitis.

Comparing Physician and Patient Reports of Psoriatic Arthritis Remission

Comparing Physician and Patient Reports of Psoriatic Arthritis Remission

By

Researchers compared definitions of remission and low disease activity in patients with psoriatic arthritis.

Low Incidence of Vertebral Fractures Observed in Early Spondyloarthritis

Low Incidence of Vertebral Fractures Observed in Early Spondyloarthritis

By

The incidence of vertebral fracture in SpA was lower than that reported in previous studies.

Comparing Remission, Low Disease Definitions in Psoriatic Arthritis

Comparing Remission, Low Disease Definitions in Psoriatic Arthritis

By

Investigators examined the performance of various definitions in patients with PsA and psoriasis.

Red Cell Distribution Width Linked to Cardiovascular Disease Risk Factors in Spondyloarthritis

Red Cell Distribution Width Linked to Cardiovascular Disease Risk Factors in Spondyloarthritis

By

CVD risk factors were associated with red blood cell distribution and albumin and red blood cell distribution was also associated with age, albumin, hemoglobin, race, HLAB27 status, CRP, and statin treatment.

Assessing the Accuracy of Questionnaire-Based Screening Tools for Detection of Psoriatic Arthritis

Assessing the Accuracy of Questionnaire-Based Screening Tools for Detection of Psoriatic Arthritis

By

Researchers reviewed the accuracy and characteristics of questionnaire-based PsA screening tools.

Workplace, Clinical Factors Linked to Employment Outcomes in Axial Spondyloarthritis

Workplace, Clinical Factors Linked to Employment Outcomes in Axial Spondyloarthritis

By

Data identified both clinical and employment factors that may predict poor work outcomes in patients with axial spondyloarthritis.

Spinal Radiographic Progression May Be Observed Early in Disease Course for axSpA

Spinal Radiographic Progression May Be Observed Early in Disease Course for axSpA

By

Higher radiographic progression was associated with increased inflammation and damage in early axial spondyloarthritis.

Gender-Specific Approaches Not Warranted for Early Axial Spondyloarthritis Diagnosis

Gender-Specific Approaches Not Warranted for Early Axial Spondyloarthritis Diagnosis

By

Results do not suggest that separate diagnostic strategies for men and women are required.

Filgotinib Effective for Treatment of Active Psoriatic Arthritis

Filgotinib Effective for Treatment of Active Psoriatic Arthritis

By

Data show that filgotinib is effective for the treatment of active psoriatic arthritis.

TNFi Therapy Did Not Prevent Joint Ankylosis in Young Patients With Spondyloarthritis

TNFi Therapy Did Not Prevent Joint Ankylosis in Young Patients With Spondyloarthritis

By

TNFi therapy failed to prevent the development of joint ankylosis despite a substantial reduction in inflammation with TNFi therapy.

Clinical Characteristics of Patients With AS Who Discontinue TNFis Explored

Clinical Characteristics of Patients With AS Who Discontinue TNFis Explored

By

To compare the characteristics of patients who discontinued TNFis with those who did not, researchers used the Corrona PsA/SpA Registry to identify patients with AS who were on a TNFi and had ≥2 follow-up visits.

Differences in Ankylosing Spondylitis Outcomes Vary by Gender

Differences in Ankylosing Spondylitis Outcomes Vary by Gender

By

Clinical improvements during treatment with TNF-α inhibitors was comparable between men and women with ankylosing spondylitis.

Ixekizumab Tops Placebo in Axial Spondyloarthritis

Ixekizumab Tops Placebo in Axial Spondyloarthritis

For patients with active radiographic axSpA and prior inadequate response or intolerance to 1 or 2 TNFi, ixekizumab treatment results in significant improvements vs placebo.

Sustained Joint and Skin Improvement Found With Bimekizumab in Psoriatic Arthritis

Sustained Joint and Skin Improvement Found With Bimekizumab in Psoriatic Arthritis

Christopher T. Ritchlin, MD, MPH, discusses updated bimekizumab data from the BE-ACTIVE trial.

Statins May Decrease C-Reactive Protein Levels in Psoriatic Arthritis

Statins May Decrease C-Reactive Protein Levels in Psoriatic Arthritis

By

Statin therapy was associated lower CRP levels in psoriatic arthritis treated with statins, possibly indicating decreased systemic inflammation.

Sign Up for Free e-newsletters